Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Q: The department did studies to identify factors contributing to cancer rates and determine the best approach to prevention and screening. The regions are in Erie, Warren and Suffolk counties and on Staten Island. The meeting schedule is online . Investigators found Warren County had the highest rates of all cancers in the state. Contributing factors were smoking, alcohol consumption, obesity and HPV infection. A meeting is scheduled Nov. 7 at Adirondack Community College in Queensbury. The East Buffalo/Cheektowaga area was found to have elevated numbers of colorectal, kidney, prostate, oral, esophageal and lung cancers. Tobacco was noted as a contributing factor. A meeting is set for Oct. 22 at Buffalo Museum of Science.

A: Meetings set to discuss higher cancer rates in 4 NY regions.
****
Q: Teva Pharmaceutical Industries Ltd's rival migraine headache preventer is excluded on one list and patients can pay more for it in some cases on a second list, the note said. As with rival PBMs Express Scripts and CVS Health Corp, OptumRx's lists of covered drugs, or formularies, cover tens of millions of consumers who receive their healthcare from employers and health insurers. About 39 million Americans suffer from migraine headaches, according to the Migraine Research Foundation, and global migraine drug sales could reach $8.7 billion by 2026, according to analytics firm GlobalData. OptumRx's decision secures easier access to customers for Lilly's Emgality at all three of the biggest PBMs - including CVS and Express Scripts - and gives Amgen's Aimovig a leg up after CVS decided not to include it on its preferred drug list. Teva's Ajovy only has preferred status at CVS, while Amgen also has it at Express Scripts, part of Cigna Corp. "We are pleased that all three companies have chosen Emgality to be one of the preferred medications, making it accessible to even more patients suffering from migraine," Lilly said in an emailed statement. Inclusion on a preferred drugs list by the largest PBMs and health insurers is critically important for sales of new medicines. Increasingly, PBMs are choosing a subset of treatments for their coverage list when there are multiple treatments that are considered equivalent. The three treatments, approved by the U.S. Food and Drug Administration last year, belong to a class of drugs called CGRP inhibitors that have proven effective in helping to prevent migraines. A Teva spokeswoman said the company is committed to increasing access to Ajovy regardless of formulary decisions and is still offering discounts that allow patients to pay nothing in some cases, regardless of insurance. "Since Ajovy injection launched in September, we have experienced strong demand and steady growth, and we continue discussions with payers," the spokeswoman said. An Amgen spokeswoman said that the company was pleased with the decision and is committed to ensuring affordable access to its drug. Amgen, which shares Aimovig U.S. revenue with Novartis AG, earlier this week reported fourth-quarter sales of $95 million, nearly doubling Wall Street estimates. The OptumRx decision becomes effective Feb. 1. The OptumRx select formulary relegates Teva's drug to a lower access level that would typically require a higher out-of-pocket cost, it said. PBMs typically extract discounts from drugmakers in return for favorable placement on their preferred list of covered drugs, such as through a low co-payment, or coinsurance payment, for their members. All three migraine drugs have a list price of $575 a month, or $6,900 a year. Those prices do not reflect the rebates and discounts to PBMs, who design and negotiate benefits for employers and insurers. All three drugmakers are providing a limited duration supply of the new drugs at no cost directly to patients in addition to other assistance programs. Amgen's Aimovig was first-to-market from the new class. But the rivals from Teva and Lilly followed soon after. The three large PBMs together cover the majority of the more than 150 million Americans who receive benefits through their employers. Their clients, including insurers and corporations, may choose not to follow a PBM's recommendations on coverage, but that typically would cost more. Amgen shares were off 28 cents at $186.63, Lilly was up nearly 1 percent at $120.90 and Teva shares traded in New York were down nearly 1 percent at $19.69.

A: Exclusive: Top U.S. insurer to cover Amgen, Eli Lilly migraine drugs, exclude Teva.
****
Q: The ministry has proposed that the government issue an executive order banning the devices in the public interest, saying it was needed to ensure e-cigarettes don't become an "epidemic" among children and young adults. "E-cigarettes and similar technologies that encourage tobacco use or adversely impact public health are hazardous for an active as well as passive user," the health ministry said in an internal note seen by Reuters that the federal cabinet is expected to consider. Health officials are proposing jail terms of up to three years, with a penalty of up to 500,000 rupees ($7,000), for repeat offenders against the new rules, according to a draft of the executive order. First-time offenders would face a prison term of up to one year and a fine of 100,000 rupees. Such orders are typically issued in India as an emergency measure when parliament is not in session. It can lapse if it is not approved when lawmakers convene against in the next session, which will most likely be held around November. It was not immediately clear whether the draft executive order will face changes, or when it will be approved. India's health ministry did not respond to a request for comment from Reuters. The ministry's plans would deal a blow to U.S.-based Juul Labs Inc, which is hoping to launch its e-cigarette in India and has hired several senior executives in recent months. Philip Morris also has plans to launch its heat-not-burn smoking device in India, Reuters has reported. Advocates for the devices say e-cigarettes are far less harmful than smoking tobacco, because users do not inhale the same dangerous matter. But many tobacco-control activists are opposed to e-cigarettes, saying they could lead to nicotine addiction and push people to consume tobacco. "There is evidence that these products are a gateway to tobacco products and induce adolescents and young adults to nicotine use leading to addiction," the health ministry said in the document. India has 106 million adult smokers, second only to China in the world, making it a lucrative market for firms such as Juul and Philip Morris. More than 900,000 people die each year in the country due to tobacco-related illnesses. Sixteen state governments in India have prohibited e-cigarettes but there is as yet no federal legislation to deal with what the health ministry termed the "hazardous product". Justifying its call for a ban, the health ministry argued that e-cigarettes can also be used as delivery devices for other substances such as cannabis, and could promote dual use with conventional cigarettes. "These devices are injurious to health and proliferation of these products has a negative impact on public health," the draft said. Reuters reported in March the health ministry had called for Juul's entry into India to be blocked, saying such products were "addictive and could potentially undermine our tobacco control efforts". Juul, whose sleek vaping devices that resemble USB flash drives have become a sensation in the United States, has previously said it aims to improve the lives of smokers by offering a "satisfying alternative to combustible cigarettes".

A:
Exclusive: India proposes ban on e-cigarettes, with jail terms for offenders - government documents.
****